EUVIMEDEUVIMED entdecken
Open Access

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

Steven E Nissen, Venu Menon, Stephen J Nicholls, Danielle Brennan, Luke Laffin, Paul Ridker, Kausik K Ray, Denise Mason, John J P Kastelein, Leslie Cho, Peter Libby, Na Li und 3 weitere

JAMA · 11.07.2023 · 330 (2) · 131

DOI: 10.1001/jama.2023.9696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 11.07.2023. Verfasst von Steven E Nissen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Myocardial Infarction, Stroke. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients without a prior cardiovascular event (primary prevention) have not been fully described.

Objective

To determine the effects of bempedoic acid on cardiovascular outcomes in primary prevention patients. Design, Setting, and Participants This masked, randomized clinical trial enrolled 13 970 statin-intolerant patients (enrollment December 2016 to August 2019 at 1250 centers in 32 countries), including 4206 primary prevention patients.

Interventions

Participants were randomized to oral bempedoic acid, 180 mg daily (n = 2100), or matching placebo (n = 2106). Main Outcome Measures The primary efficacy measure was the time from randomization to the first occurrence of any component of a composite of cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization.

Results

Mean participant age was 68 years, 59% were female, and 66% had diabetes. From a mean baseline of 142.2 mg/dL, compared with placebo, bempedoic acid reduced low-density lipoprotein cholesterol levels by 30.2 mg/dL (21.3%) and high-sensitivity C-reactive protein levels by 0.56 mg/L (21.5%), from a median baseline of 2.4 mg/L. Follow-up for a median of 39.9 months was associated with a significant risk reduction for the primary end point (111 events [5.3%] vs 161 events [7.6%]; adjusted hazard ratio [HR], 0.70 [95% CI, 0.55-0.89]; P = .002) and key secondary end points, including the composite of cardiovascular death, MI, or stroke (83 events [4.0%] vs 134 events [6.4%]; HR, 0.64 [95% CI, 0.48-0.84]; P < .001); MI (29 events [1.4%] vs 47 events [2.2%]; HR, 0.61 [95% CI, 0.39-0.98]); cardiovascular death (37 events [1.8%] vs 65 events [3.1%]; HR, 0.61 [95% CI, 0.41-0.92]); and all-cause mortality (75 events [3.6%] vs 109 events [5.2%]; HR, 0.73 [95% CI, 0.54-0.98]). There was no significant effect on stroke or coronary revascularization. Adverse effects with bempedoic acid included a higher incidence of gout (2.6% vs 2.0%), cholelithiasis (2.5% vs 1.1%), and increases in serum creatinine, uric acid, and hepatic enzyme levels.

Conclusions

In a subgroup of high-risk primary prevention patients, bempedoic acid treatment was associated with reduced major cardiovascular events. Trial Registration ClinicalTrials.gov Identifier: NCT02993406

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesMyocardial InfarctionStrokeHumansFemaleAgedMalePrimary PreventionDicarboxylic AcidsFatty Acids

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidDicarboxylic AcidsFatty Acids

Autor:innen und Institutionen

  • Cleveland Clinic, Cleveland, Ohio.
  • Victorian Heart Institute, Monash University, Melbourne, Australia.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Imperial College London, London, United Kingdom.
  • University of Amsterdam Academic Medical Center, Amsterdam, the Netherlands.
  • Esperion Therapeutics Inc, Ann Arbor, Michigan.

Zitieren

APA

Nissen, S. E., Menon, V., Nicholls, S. J., Brennan, D., Laffin, L., Ridker, P., Ray, K. K., Mason, D., Kastelein, J. J. P., Cho, L., Libby, P., Li, N., Foody, J., Louie, M. J., & Lincoff, A. M. (2023). Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA, 330(2), 131. https://doi.org/10.1001/jama.2023.9696

Vancouver

Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023;330(2):131. doi:10.1001/jama.2023.9696

BibTeX
@article{Nissen2023,
  author = {Nissen, Steven E and Menon, Venu and Nicholls, Stephen J and Brennan, Danielle and Laffin, Luke and Ridker, Paul and Ray, Kausik K and Mason, Denise and Kastelein, John J P and Cho, Leslie and Libby, Peter and Li, Na and Foody, JoAnne and Louie, Michael J and Lincoff, A Michael},
  title = {Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {2},
  pages = {131},
  doi = {10.1001/jama.2023.9696}
}
Kostenlos starten →